image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 2.935
-3.1 %
$ 220 M
Market Cap
-6.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one OSUR stock under the worst case scenario is HIDDEN Compared to the current market price of 2.94 USD, OraSure Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one OSUR stock under the base case scenario is HIDDEN Compared to the current market price of 2.94 USD, OraSure Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one OSUR stock under the best case scenario is HIDDEN Compared to the current market price of 2.94 USD, OraSure Technologies, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OSUR

image
$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
186 M REVENUE
-54.17%
-28.2 M OPERATING INCOME
-86.43%
-19.5 M NET INCOME
-36.34%
27.4 M OPERATING CASH FLOW
-80.67%
-39 M INVESTING CASH FLOW
-58.99%
-4.18 M FINANCING CASH FLOW
-38.14%
934 K REVENUE
-97.51%
-18.3 M OPERATING INCOME
-47.08%
-16 M NET INCOME
-48.60%
-19.7 M OPERATING CASH FLOW
-18103.67%
370 K INVESTING CASH FLOW
106.74%
-953 K FINANCING CASH FLOW
-758.56%
Balance Sheet OraSure Technologies, Inc.
image
Current Assets 333 M
Cash & Short-Term Investments 268 M
Receivables 23.8 M
Other Current Assets 41.6 M
Non-Current Assets 146 M
Long-Term Investments 28.3 M
PP&E 58.7 M
Other Non-Current Assets 59.4 M
55.82 %4.97 %8.68 %5.90 %12.24 %12.39 %Total Assets$479.7m
Current Liabilities 33.5 M
Accounts Payable 8.17 M
Short-Term Debt 2.17 M
Other Current Liabilities 23.1 M
Non-Current Liabilities 35.8 M
Long-Term Debt 12.4 M
Other Non-Current Liabilities 23.4 M
11.79 %3.13 %33.38 %17.94 %33.76 %Total Liabilities$69.3m
EFFICIENCY
Earnings Waterfall OraSure Technologies, Inc.
image
Revenue 186 M
Cost Of Revenue 110 M
Gross Profit 79.4 M
Operating Expenses 108 M
Operating Income -28.2 M
Other Expenses -8.75 M
Net Income -19.5 M
200m200m150m150m100m100m50m50m00(50m)(50m)186m(110m)79m(108m)(28m)9m(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
42.72% GROSS MARGIN
42.72%
-15.20% OPERATING MARGIN
-15.20%
-10.49% NET MARGIN
-10.49%
-4.75% ROE
-4.75%
-4.07% ROA
-4.07%
-7.01% ROIC
-7.01%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OraSure Technologies, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -19.5 M
Depreciation & Amortization 10.9 M
Capital Expenditures -3.8 M
Stock-Based Compensation 11.9 M
Change in Working Capital 18.8 M
Others 3.35 M
Free Cash Flow 23.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OraSure Technologies, Inc.
image
Wall Street analysts predict an average 1-year price target for OSUR of $4.25 , with forecasts ranging from a low of $4 to a high of $4.5 .
OSUR Lowest Price Target Wall Street Target
4 USD 36.29%
OSUR Average Price Target Wall Street Target
4.25 USD 44.80%
OSUR Highest Price Target Wall Street Target
4.5 USD 53.32%
Price
Max Price Target
Min Price Target
Average Price Target
55554444333322Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership OraSure Technologies, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
761 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Orasure Technologies: Multiple Shots To Deliver Value OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth. seekingalpha.com - 3 weeks ago
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call. seekingalpha.com - 1 month ago
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago. zacks.com - 1 month ago
OraSure Technologies: Historically Cheap OraSure Technologies shares have dipped below $3 since my last writing, making shares even cheaper. Recent developments at the company include the acquisition of Sherlock Biosciences and the announcement of a $40 million share repurchase program. OSUR is enhancing business efficiency through cost cuts and aims to expand gross margins to 50% by year-end 2025, mitigating acquisition-related cash burn. seekingalpha.com - 1 month ago
OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. globenewswire.com - 1 month ago
OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. globenewswire.com - 2 months ago
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Inc. 2024 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.22 per share a year ago. zacks.com - 3 months ago
OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025. globenewswire.com - 4 months ago
OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock? OraSure (OSUR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
New Strong Buy Stocks for January 27th ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024. zacks.com - 4 months ago
Should Value Investors Buy OraSure Technologies (OSUR) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 months ago
8. Profile Summary

OraSure Technologies, Inc. OSUR

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 220 M
Dividend Yield 0.00%
Description OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Contact 220 East First Street, Bethlehem, PA, 18015 https://www.orasure.com
IPO Date Nov. 17, 1986
Employees 501
Officers Mr. Jason Michael Plagman Vice President of Investor Relations Ms. Kathleen Gallagher Weber Chief Product Officer Mr. Stefano Taucer General Counsel & Corporate Secretary Mr. David A. Rappaport C.F.A. Senior Vice President Corporate Development, Strategy & Integration Mr. Kenneth J. McGrath Chief Financial Officer Amy Steigerwalt Senior Vice President of Human Resources Ms. Michele Anthony Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary Ms. Carrie Eglinton Manner President, Chief Executive Officer & Director Mr. Rafal Iwasiow Ph.D. Vice President of Science, Innovation & Technology Mr. Zachary Wert Senior Vice President of Global Operations